Tego Science, Inc. Logo

Tego Science, Inc.

Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.

191420 | KO

Overview

Corporate Details

ISIN(s):
KR7191420009
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 93 (마곡동, 테고사이언스), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Tego Science, Inc. is a biopharmaceutical company specializing in advanced regenerative medicine, leveraging proprietary cell culture technology. Founded in 2001, the company develops, manufactures, and commercializes cell therapies for skin regeneration and wound healing. Its key approved products include Holoderm® for severe burns, Kaloderm® for diabetic foot ulcers, and Rosmir® for wrinkle improvement. Beyond therapeutics, Tego Science offers Neoderm®, a 3D cultured skin model as an alternative to animal testing, and provides Contract Development and Manufacturing Organization (CDMO) services from its GMP facility. The company maintains a robust R&D pipeline, with candidates like TPX-115 for rotator cuff tears, and operates a globally compliant allogeneic cell bank to ensure stable production of its innovative treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-27 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-05-26 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 111.0 KB
2025-05-23 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 108.1 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.1 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.0 KB
2025-03-19 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.4 MB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 12.2 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 134.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.4 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 138.0 KB
2025-02-14 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-02-14 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청등결정) (회전근개 부분층 파열 개선을 위한 동종피부유래섬유아세포(TPX-11…
Korean 10.2 KB
2025-01-31 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB

Automate Your Workflow. Get a real-time feed of all Tego Science, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Tego Science, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Tego Science, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.